Cholangiocarcinoma: Biology, Clinical Management, and Pharmacological Perspectives

  1. Macias, Rocio I. R. 1234
  1. 1 Laboratory of Experimental Hepatology and Drug Targeting (HEVEFARM), University of Salamanca, IBSAL, 37007 Salamanca, Spain
  2. 2 National Institute of Health Carlos III, CIBERehd, 28029 Madrid, Spain
  3. 3 Department of Physiology and Pharmacology, Campus Miguel de Unamuno E.D. B-17, University of Salamanca, 37007 Salamanca, Spain
  4. 4 Universidad de Salamanca
    info

    Universidad de Salamanca

    Salamanca, España

    ROR https://ror.org/02f40zc51

Mostrar afiliaciones +
Revista:
ISRN Hepatology

ISSN: 2314-4041

Año de publicación: 2014

Volumen: 2014

Páginas: 1-13

Tipo: Artículo

DOI: 10.1155/2014/828074 GOOGLE SCHOLAR lock_openAcceso abierto editor

Otras publicaciones en: ISRN Hepatology

Resumen

Cholangiocarcinoma (CCA), or tumor of the biliary tree, is a rare and heterogeneous group of malignancies associated with a very poor prognosis. Depending on their localization along the biliary tree, CCAs are classified as intrahepatic, perihilar, and distal, and these subtypes are now considered different entities that differ in tumor biology, the staging system, management, and prognosis. When diagnosed, an evaluation by a multidisciplinary team is essential; the team must decide on the best therapeutic option. Surgical resection of tumors with negative margins is the best option for all subtypes of CCA, although this is only achieved in less than 50% of cases. Five-year survival rates have increased in the recent past owing to improvements in imaging techniques, which permits resectability to be predicted more accurately, and in surgery. Chemotherapy and radiotherapy are relatively ineffective in treating nonoperable tumors and the resistance of CCA to these therapies is a major problem. Although the combination of gemcitabine plus platinum derivatives is the pharmacological treatment most widely used, to date there is no standard chemotherapy, and new combinations with targeted drugs are currently being tested in ongoing clinical trials. This review summarizes the biology, clinical management, and pharmacological perspectives of these complex tumors.

Referencias bibliográficas

  • (2013), Annals of Oncology, 24, pp. 1667, 10.1093/annonc/mds652
  • 10.1111/j.1572-0241.2004.40052.x
  • (2007), World Journal of Gastroenterology, 13, pp. 1500, 10.3748/wjg.v13.i10.1500
  • 10.1016/j.cgh.2012.09.009
  • 10.1055/s-0031-1272839
  • (2012), World Journal of Gastrointestinal Oncology, 4, pp. 94, 10.4251/wjgo.v4.i5.94
  • (2012), Journal of Clinical Investigation, 122, pp. 2911, 10.1172/JCI63212
  • (2012), Journal of Clinical Investigation, 122, pp. 3914, 10.1172/JCI63065
  • (2013), Gastroenterology, 144, pp. 829, 10.1053/j.gastro.2013.01.001
  • (2010)
  • 10.1200/JCO.2011.35.6519
  • (2013), Annals of Surgical Oncology, 20, pp. 277, 10.1245/s10434-012-2486-0
  • 10.1111/j.1477-2574.2010.00271.x
  • 10.1111/j.1478-3231.2006.01350.x
  • 10.1053/j.gastro.2009.02.038
  • 10.1002/bjs.4815
  • 10.1097/01.sla.0000251366.62632.d3
  • 10.1186/1471-2407-2-10
  • 10.1136/gut.48.6.816
  • 10.1053/jhep.2001.25087
  • 10.1007/s11605-007-0282-0
  • 10.1016/j.jhep.2011.11.015
  • 10.1016/j.cld.2007.11.003
  • 10.1093/ije/25.5.933
  • 10.1002/hep.24351
  • 10.1053/j.gastro.2004.12.048
  • 10.1016/j.jhep.2012.02.022
  • 10.1002/hep.24397
  • (2014), Molecular Cancer Research, 12, pp. 91, 10.1158/1541-7786.MCR-13-0503
  • (1971), Michigan Medicine, 70, pp. 911
  • (2000), Cancer Research, 60, pp. 184
  • 10.1002/hep.22310
  • (2005), World Journal of Gastroenterology, 11, pp. 4644, 10.3748/wjg.v11.i30.4644
  • 10.2353/ajpath.2009.080012
  • 10.1097/00000658-199803000-00012
  • 10.1053/j.gastro.2006.10.037
  • 10.1053/j.gastro.2005.03.010
  • 10.1002/hep.510300522
  • 10.1016/j.lfs.2005.10.015
  • 10.1053/jhep.2002.34435
  • 10.1002/path.1779
  • 10.1038/sj.bjc.6604129
  • (1997), American Journal of Pathology, 151, pp. 1685
  • 10.3748/wjg.v16.i32.4047
  • (2002), Gastroenterology, 122, pp. 985, 10.1053/gast.2002.32410
  • (2012), Zeitschrift für Gastroenterologie, 50, pp. 5
  • 10.1002/hep.20294
  • 10.1158/0008-5472.CAN-06-1078
  • 10.1093/carcin/bgl249
  • 10.1097/01.coc.0000204402.29830.08
  • 10.1016/j.dld.2008.02.015
  • 10.1016/S0046-8177(98)90229-5
  • 10.1016/j.jss.2006.05.031
  • (2000), Journal of Hepatology, 33, pp. 520, 10.1016/S0168-8278(00)80002-1
  • 10.1007/s002619900410
  • 10.1002/hep.23071
  • 10.1080/13651820801992617
  • 10.1148/rg.293085729
  • 10.1016/j.jamcollsurg.2007.07.002
  • (2011), Hepato-Gastroenterology, 58, pp. 265
  • 10.1097/MCG.0b013e31806daf89
  • (2010), European Journal of Medical Research, 15, pp. 357, 10.1186/2047-783X-15-8-357
  • 10.1016/S0002-9270(99)00744-3
  • 10.1097/MOG.0b013e328325a894
  • (2010), World Journal of Gastrointestinal Oncology, 2, pp. 136, 10.4251/wjgo.v2.i3.136
  • 10.1007/s11605-013-2363-6
  • 10.1111/j.1432-2277.2010.01108.x
  • 10.1097/01.sla.0000179678.13285.fa
  • 10.2214/AJR.10.4937
  • 10.1016/0140-6736(92)92752-2
  • (2013), HPB, 15, pp. 372, 10.1111/j.1477-2574.2012.00588.x
  • 10.1200/JCO.2006.09.8657
  • 10.1002/cncr.25625
  • 10.1007/s00270-011-0142-x
  • 10.1023/A:1008352123009
  • 10.1023/B:DRUG.0000011797.09549.53
  • 10.1007/s00280-005-0095-3
  • 10.1002/cncr.20368
  • 10.1007/s00280-007-0673-7
  • 10.1200/JCO.2005.51.008
  • 10.1002/cncr.21591
  • 10.1245/s10434-007-9539-9
  • 10.1007/s00280-011-1657-1
  • 10.1007/s00280-009-1115-5
  • 10.1093/annonc/mdi046
  • 10.1002/cncr.21741
  • 10.1093/annonc/mdh351
  • 10.1038/sj.bjc.6603334
  • 10.1007/s00280-009-1069-7
  • (2013), Cancer Chemotherapy and Pharmacology, 71, pp. 973, 10.1007/s00280-013-2090-4
  • 10.1056/NEJMoa0908721
  • 10.1038/sj.bjc.6605779
  • 10.1002/cncr.20753
  • 10.1159/000320462
  • 10.3109/0284186X.2010.500300
  • 10.1038/sj.bjc.6602208
  • 10.1007/s00534-007-1279-5
  • 10.1056/NEJMoa0708857
  • 10.1038/sj.bjc.6605458
  • 10.1007/s10637-011-9719-0
  • 10.1016/j.ejca.2011.11.017
  • 10.1200/JCO.2010.33.9473
  • 10.1200/JCO.2005.05.3579
  • 10.1007/s00280-009-0927-7
  • 10.1200/JCO.2010.28.4075
  • 10.1016/S1470-2045(10)70247-3
  • 10.1016/S1470-2045(09)70333-X
  • (2012), Annals of Oncology, 23, pp. 2341, 10.1093/annonc/mds008
  • 10.1016/S1470-2045(11)70301-1
  • (2013), British Journal of Cancer, 109, pp. 915, 10.1038/bjc.2013.432
  • 10.1016/j.humpath.2009.10.002
  • (2005), Cancer Research, 65, pp. 3003, 10.1158/0008-5472.CAN-04-3586
  • 10.1097/01.cad.0000217433.48870.37
  • 10.1038/sj.bjc.6604988
  • (2012), Molecular Pharmacology, 9, pp. 1693, 10.1021/mp300028a
  • 10.1186/1471-2407-12-109
  • (2013), Hepatology, 58, pp. 1065
  • 10.6064/2012/428139
  • (1997), Journal of Clinical Investigation, 100, pp. 2714, 10.1172/JCI119816
  • 10.1021/bc970061v
  • (1998), Anticancer Research, 18, pp. 1641
  • 10.1021/bc9901088
  • (1998), International Journal of Cancer, 78, pp. 346, 10.1002/(SICI)1097-0215(19981029)78:3<346::AID-IJC15>3.0.CO;2-4
  • (2001), Journal of Pharmacology and Experimental Therapeutics, 297, pp. 1106
  • (1998), Journal of Lipid Research, 39, pp. 1792, 10.1016/S0022-2275(20)32166-0
  • (2012), La proteína ASBT podría utilizarse en el tratamiento del colangiocarcinoma como diana para la vectorización de derivados citostáticos de ácidos biliares, pp. 195
  • (2013), Expert Opinion on Investigational Drugs, 22, pp. 141, 10.1517/13543784.2013.741586
  • (2012), Advances in Therapy, 29, pp. 925, 10.1007/s12325-012-0060-6
  • (2004), Molecular Cancer Therapeutics, 3, pp. 299
  • (2013), PLoS ONE, 8